Royal Bank of Canada
AZN icon

Royal Bank of Canada’s AstraZeneca AZN Stock Holding History

Royal Bank of Canada’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.05B Buy
10,386,455
+8,703,790
+517% +$1.68B 0.36% 52
2025
Q4 		$309M Sell
1,682,665
-11,671
-0.7% -$2.05M 0.05% 310
2025
Q3 		$260M Sell
1,694,336
-32,282
-2% -$4.89M 0.04% 357
2025
Q2 		$241M Buy
1,726,618
+461,921
+37% +$64.7M 0.04% 343
2025
Q1 		$186M Buy
1,264,697
+48,291
+4% +$6.99M 0.04% 366
2024
Q4 		$159M Sell
1,216,406
-29,190
-2% -$4.09M 0.03% 421
2024
Q3 		$194M Buy
1,245,596
+25,828
+2% +$4.17M 0.04% 369
2024
Q2 		$190M Buy
1,219,768
+20,107
+2% +$3.03M 0.04% 331
2024
Q1 		$163M Buy
1,199,661
+24,348
+2% +$3.22M 0.04% 367
2023
Q4 		$158M Buy
1,175,313
+23,216
+2% +$3.02M 0.04% 382
2023
Q3 		$156M Buy
1,152,097
+33,922
+3% +$4.63M 0.04% 352
2023
Q2 		$160M Sell
1,118,175
-28,913
-3% -$4.25M 0.04% 364
2023
Q1 		$159M Buy
1,147,088
+81,861
+8% +$11M 0.05% 347
2022
Q4 		$144M Sell
1,065,227
-101,958
-9% -$12.8M 0.04% 382
2022
Q3 		$128M Sell
1,167,185
-22,020
-2% -$2.79M 0.04% 377
2022
Q2 		$157M Sell
1,189,205
-14,795
-1% -$1.94M 0.05% 328
2022
Q1 		$160M Sell
1,204,000
-28,111
-2% -$3.37M 0.04% 356
2021
Q4 		$144M Sell
1,232,111
-27,552
-2% -$3.24M 0.03% 417
2021
Q3 		$151M Buy
1,259,663
+272,731
+28% +$31.7M 0.04% 371
2021
Q2 		$118M Sell
986,932
-36,439
-4% -$4M 0.03% 441
2021
Q1 		$102M Buy
1,023,371
+33,916
+3% +$3.41M 0.03% 455
2020
Q4 		$98.9M Buy
989,455
+86,758
+10% +$9.19M 0.03% 459
2020
Q3 		$98.9M Buy
902,697
+712
+0.1% +$79.2K 0.04% 390
2020
Q2 		$95.4M Buy
901,985
+14,810
+2% +$1.53M 0.04% 374
2020
Q1 		$79.2M Buy
887,175
+56,480
+7% +$5.32M 0.04% 356
2019
Q4 		$82.8M Buy
830,695
+23,506
+3% +$2.21M 0.03% 438
2019
Q3 		$72M Sell
807,189
-4,940
-0.6% -$428K 0.03% 468
2019
Q2 		$67M Sell
812,129
-69,115
-8% -$5.42M 0.03% 475
2019
Q1 		$71.3M Sell
881,244
-186,819
-17% -$14.7M 0.03% 440
2018
Q4 		$81.1M Sell
1,068,063
-45,572
-4% -$3.56M 0.04% 382
2018
Q3 		$88.1M Sell
1,113,635
-96,901
-8% -$7.33M 0.04% 390
2018
Q2 		$85M Sell
1,210,536
-222,828
-16% -$16M 0.04% 375
2018
Q1 		$100M Sell
1,433,364
-35,971
-2% -$2.49M 0.04% 340
2017
Q4 		$102M Buy
1,469,335
+88,725
+6% +$5.98M 0.04% 332
2017
Q3 		$93.6M Buy
1,380,610
+452,907
+49% +$28.6M 0.04% 324
2017
Q2 		$63.3M Buy
927,703
+100,943
+12% +$6.59M 0.03% 443
2017
Q1 		$51.5M Buy
826,760
+241,378
+41% +$14.1M 0.03% 500
2016
Q4 		$32M Buy
585,382
+11,500
+2% +$653K 0.02% 756
2016
Q3 		$37.7M Buy
573,882
+219,612
+62% +$14.4M 0.02% 632
2016
Q2 		$21.4M Sell
354,270
-6,872
-2% -$399K 0.01% 913
2016
Q1 		$20.3M Buy
361,142
+67,852
+23% +$4.08M 0.01% 918
2015
Q4 		$19.9M Sell
293,290
-10,099
-3% -$662K 0.01% 973
2015
Q3 		$19.3M Buy
303,389
+116,413
+62% +$7.66M 0.01% 786
2015
Q2 		$11.9M Buy
186,976
+81,066
+77% +$5.55M 0.01% 1124
2015
Q1 		$7.25M Buy
105,910
+3,895
+4% +$271K 0.01% 1381
2014
Q4 		$7.18M Buy
102,015
+2,308
+2% +$165K ﹤0.01% 1415
2014
Q3 		$7.12M Sell
99,707
-17,597
-15% -$1.29M ﹤0.01% 1403
2014
Q2 		$8.72M Sell
117,304
-224,946
-66% -$16.3M 0.01% 1293
2014
Q1 		$22.2M Buy
342,250
+37,474
+12% +$2.42M 0.02% 713
2013
Q4 		$18.1M Sell
304,776
-3,538
-1% -$192K 0.01% 848
2013
Q3 		$16M Buy
308,314
+40,276
+15% +$2.02M 0.01% 855
2013
Q2 		$12.7M Buy
+268,038
New +$13.6M 0.01% 923

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Royal Bank of Canada's AZN Position: Q1 2026 in Review

Royal Bank of Canada increased its AstraZeneca (AZN) stake by 517% in Q1 2026, buying an estimated $1.68B and bringing the position to 10,386,455 shares worth $2.05B. The position accounts for 0.36% of the portfolio, ranked #52.

Royal Bank of Canada first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,381 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Royal Bank of Canada held 10,386,455 shares of AstraZeneca worth $2.05B as of Q1 2026.
  • Royal Bank of Canada bought 8,703,790 AstraZeneca shares in Q1 2026, an estimated $1.68B.
  • AstraZeneca made up 0.36% of Royal Bank of Canada's portfolio in Q1 2026, its #52 holding.
  • Royal Bank of Canada first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
  • 1,381 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.